Rejuvenate Bio, a biotechnology company developing gene therapies for age-related and chronic diseases, today announced the closing of a $6 million financing round led by VCapital, with participation from Merck Animal Health, Kendall Capital Partners, Connecticut Innovations and Digitalis. In addition to the financing, Rejuvenate Bio and Merck Animal Health have entered into a strategic research and development collaboration focused on advancing a novel gene therapy program in animal health. T

June 8, 2026 -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in Parkinson's disease in the SLEIPNIR Phase 2a platform trial, in collaboration with Haukeland University Hospital, Bergen, Norway. SLEIPNIR is a multi-arm Phase 2a clinical trial platform designed to evaluate investigational disease-modifying therapies in Parkinson's disease, with focus on brain penetration, biological ta

Incyte announced Monday an agreement to acquire Vega Therapeutics, a wholly-owned subsidiary of Star Therapeutics, for up to $2 billion, confirming rumours first reported by the Financial Times a day earlier. The deal — which includes $1.25 billion upfront — is focused on the investigational monoclonal antibody VGA039 for von Willebrand disease (VWD). "VGA039 fits directly into our strategy of building a top-tier growth company for the future," said Incyte CEO Bill Meury, who took up the reins

Roche is wagering billions of dollars on a medicine that trashes a troublesome protein instead of stifling its activity. The Swiss drugmaker on Monday reached a deal with Nurix Therapeutics to codevelop a therapy called bexobrutideg that’s nearing late-stage testing. Roche will pay Nurix $700 million up front and, in return, will split U.S. rights to the drug while gaining full ownership elsewhere. Roche will also cover 60% of the development costs and hand Nurix royalties on non-U.S. sales. N

June 8, 2026 - Kye Pharmaceuticals Inc. ("Kye"), a Canadian-based specialty pharmaceutical company focused on licensing and commercializing innovative medicines for patients in Canada, today announced that Dyanavel® XR (amphetamine extended-release) tablets are now available through pharmacies and wholesalers nationwide. Dyanavel® XR is authorized for sale in Canada for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults aged 18 years and older, as well as in children age

Transaction will add FDA Breakthrough Device-Designated technology with active U.S. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs. Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and Israel. Galmed contemplates an investment of $6 million to launch Colospan's device during H2 2026 in Europe with an initial focus on Germany, Austria and Switzerl

June 8, 2026 -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, has been selected to present Phase II updated results for BW-20805 at the European Association of Allergy & Clinical Immunology (EAACI) 2026 Congress, being held on June 12-15, 2026 in Istanbul, Türkiye. BW-20805 is an investigational siRNA therapy that targets and significantly inhibits prekallikrein (PKK), a well-validated target for hereditary angioedema (HA

June 8, 2026 --Curasight A/S ("Curasight" or "the Company") (Spotlight: CURAS) announces encouraging preliminary readout from its Phase 1 clinical trial with uTREAT® in patients with aggressive brain cancer (glioblastoma). A preliminary readout of the Phase 1 clinical trial with uTREAT® in glioblastoma, an aggressive brain cancer, has now been undertaken. The data support: The feasibility and safety of the mode of administration, super-selective intra-arterial cerebral injection (super-SIACI) w

– Preclinical NHP data demonstrate significant fat‑specific weight loss with RV‑8451, while preserving lean mass and showing no gastrointestinal adverse events – IND‑enabling studies advancing, with IND submission for RV-8451in obesity targeted for Q1 2027 – Greater fat loss in head-to-head NHP study versus orforglipron while preserving lean mass June 5, 2026 – Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on advancing cardiometabolic health, today announced pr

New real-world survey data reveal the daily impact of Huntington’s disease (HD) chorea, with over 68% of patients reporting interference with social life or emotional wellbeing1 and up to 83% of caregivers noting impact on their own daily lives.2 Following treatment with AUSTEDO or AUSTEDO XR, most patients (60-71%) reported improvement across multiple quality of life domains as a result of their improved movements.1 As a result of the patient’s reduced chorea impact, most caregivers reported l